Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹728 Cr
Revenue (TTM)
₹337 Cr
Net Profit (TTM)
₹-17 Cr
ROE
7.6 %
ROCE
10.4 %
P/E Ratio
--
P/B Ratio
1.9
Industry P/E
44.74
EV/EBITDA
-424.7
Div. Yield
0.6 %
Debt to Equity
0.2
Book Value
₹41.8
EPS
₹-1.7
Face value
1
Shares outstanding
92,100,120
CFO
₹207.62 Cr
EBITDA
₹446.12 Cr
Net Profit
₹289.22 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Themis Medicare
| -21.3 | -7.7 | -20.6 | -46.6 | -12.4 | 21.6 | 7.2 |
|
BSE Healthcare
| -4.7 | -5.8 | -5.4 | 1.3 | 23.7 | 14.0 | 10.6 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Themis Medicare
| -61.9 | 19.9 | 57.7 | 43.5 | 162.3 | 8.6 | -3.8 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Themis Medicare
|
79.2 | 727.6 | 337.4 | -22.6 | -5.8 | -4 | -- | 1.9 |
| 2,110.2 | 17,282.6 | 1,215.1 | 284.8 | 28.7 | 21.1 | 60.2 | 11.4 | |
| 656.2 | 12,893.6 | 7,266.8 | 627.5 | 11.9 | 12.6 | 20.5 | 2.4 | |
| 613.6 | 15,214.7 | 5,092.5 | 545.5 | 15.9 | 14.1 | 27.9 | 3.7 | |
| 839.3 | 13,375.6 | 7,918.4 | 429.9 | 10.7 | 7.2 | 30.9 | 2.0 | |
| 1,027.6 | 18,409.8 | 4,560.2 | 1,544.6 | 35.1 | 19.2 | 11.8 | 2.1 | |
| 1,404.5 | 16,092.2 | 1,419.3 | 20.1 | 8.4 | 0.5 | 800.5 | 2.8 | |
| 142.2 | 18,882.0 | 8,871.4 | -223.5 | 1.9 | -1.6 | -- | 2.4 | |
| 391.1 | 15,752.9 | 3,720.2 | 352.1 | 13.7 | 8.2 | 44.7 | 3.3 | |
| 1,271.5 | 20,670.6 | 3,151.0 | -10.0 | 8.4 | 2.5 | 939.6 | 4.5 |
No Review & Analysis are available.
Themis Medicare Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India and internationally. It offers active pharmaceutical ingredients (APIs) and formulations used in various therapeutic areas, including... anti-tuberculosis, analgesic and anti-inflammatory, analgesic and antispasmodic, analgesics, anesthesia, antacid-antiflatulent, anti-fungal, antibiotic, anti-diabetic, anti-emetic, anti-hypertensive, anti-allergic and anti-inflammatory, anti-allergic and appetite stimulant, anticoagulant, antifibrolytic, antimalarial, anti-muscarinic, antioxidant, calcium, cardiovascular, corticosteroid, electrolytes, expectorant, hematinic, hemostatic agent, hemostatic agent with anesthetic, hormones, immunomodulator with anti-viral, muscle relaxant, narcotic analgesic, neuropathy, nutraceuticals, PPI, probiotic, reversal for muscle relaxant, sedatives, skeletal muscle relaxant, skeletal muscle relaxant and analgesic and anti-inflammatory, vasodilator, vasopressors, and vitamins. The company was formerly known as Themis Chemicals and changed its name to Themis Medicare Limited in 2001. Themis Medicare Limited was founded in 1952 and is based in Mumbai, India. Read more
Incorporated
1969
Chairman
Dinesh S Patel
Managing Director
Sachin D Patel
Headquarters
Vapi, Gujarat
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Themis Medicare Ltd is ₹79.22 (NSE) and ₹79.00 (BSE) as of 02-Apr-2026 IST. Themis Medicare Ltd has given a return of -12.43% in the last 3 years.
Since, TTM earnings of Themis Medicare Ltd is negative, P/E ratio is not available.
The P/B ratio of Themis Medicare Ltd is 1.89 times as on 02-Apr-2026, a 39 discount to its peers’ median range of 3.10 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
45.24
|
3.35
|
|
2024
|
46.31
|
5.34
|
|
2023
|
1.89
|
3.16
|
|
2022
|
1.18
|
2.99
|
|
2021
|
0.72
|
1.18
|
The 52-week high and low of Themis Medicare Ltd are Rs 176.00 and Rs 64.95 as of 04-Apr-2026.
Themis Medicare Ltd has a market capitalisation of ₹ 728 Cr as on 02-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Themis Medicare Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹5.04
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.